Mirati Therapeutics develops novel oncology treatments targeting genetic and immunological promoters of cancer. The company provides KRAZATI for KRAS G12C-mutated non-small cell lung cancer patients. Sitravatinib, a spectrum-selective kinase inhibitor, is in Phase 3 development to overcome checkpoint resistance. The pipeline includes MRTX1719, a synthetic lethal PRMT5 inhibitor; MRTX0902, a SOS1 inhibitor improving anti-tumor efficacy; and MRTX1133, an investigational KRAS G12D compound. Mirati has collaborations with BeiGene and Zai Lab to develop and commercialize sitravatinib and adagrasib. The company was founded in 1995 and is headquartered in San Diego.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | -4.2 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -54.9% |
| Net Debt/EBITDA | 0.3 |